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10.The aim of the present study was to investigate the long-term impact of early intravenous
metoprolol in ST-segment elevation myocardial infarction (STEMI) patients in terms of
left ventricular (LV) strain with feature-tracking cardiovascular magnetic resonance
(CMR) and its association with prognosis. A total of 270 patients with first anterior
STEMI enrolled in the randomized METOCARD-CNIC clinical trial, assigned to receive
up to 15 mg intravenous metoprolol before primary percutaneous coronary intervention
versus conventional STEMI therapy, were included. LV global circumferential (GCS) and
longitudinal (GLS) strain were assessed with feature-tracking CMR at 1 week after
STEMI in 215 patients. The occurrence of major adverse cardiac events (MACE) at 5-
year follow-up was the primary end point. Among 270 patients enrolled, 17 of 139 patients
assigned to metoprolol arm and 31 of 131 patients assigned to control arm experienced
MACE (hazard ratio [HR] 0.500, 95% confidence interval [CI] 0.277 to 0.903; p = 0.022).
Impaired LV GCS and GLS strain were significantly associated with increased occurrence
of MACE (GCS: HR 1.208, 95% CI 1.076 to 1.356, p =0.001; GLS: HR 1.362, 95% CI
1.180 to 1.573, p < 0.001). On multivariable analysis, LV GLS provided incremental prog-
nostic value over late gadolinium enhancement (LGE) and LV ejection fraction (LVEF)
(LGE + LVEF chi-square = 12.865, LGE + LVEF +GLS chi-square = 18.459; p =0.012).
Patients with GLS ≥-11.5% (above median value) who received early intravenous meto-
prolol were 64% less likely to experience MACE than their counterparts with same degree
of GLS impairment (HR 0.356, 95% CI 0.129 to 0.979; p = 0.045). In conclusion, early
intravenous metoprolol has a long-term beneficial prognostic effect, particularly in
patients with severely impaired LV systolic function. LV GLS with feature-tracking CMR
early after percutaneous coronary intervention offers incremental prognostic value over
conventional CMR parameters in risk stratification of STEMI patients. © 2020 The
Author(s). Published by Elsevier Inc. This is an open access article under the CC BY
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40 The American Journal of Cardiology (www.ajconline.org)The outcome of patients with ST-segment elevation
myocardial infarction (STEMI) has significantly improved
over the last decades.1,2 However, STEMI survivors are still
at high risk of recurrent cardiovascular events such as
congestive heart failure, arrhythmia, and sudden death.3,4 In
the acute phase of STEMI, novel therapeutic approaches
aiming at reducing the ischemia-reperfusion injury are
being tested.5,6 The beneficial effect of early intravenous
b-blockade in STEMI population was demonstrated in the
Effect of Metoprolol in Cardioprotection During an Acute
Myocardial Infarction (METOCARD-CNIC) trial7,8 and
was adopted by current guidelines.3 Recently, the impact of
multidirectional left ventricular (LV) strain with feature-
tracking cardiovascular magnetic resonance (CMR) has
been studied in STEMI patients.9−14 Conflicting results
with respect to the incremental value of feature-tracking
CMR over traditional markers of infarct injury, such as LV
ejection fraction (LVEF) and infarct size with late gadolin-
ium enhancement (LGE), have been observed.9−14 The cur-
rent analysis aims at addressing 3 questions (1) whether
early intravenous metoprolol offers a long-term beneficial
effect in STEMI patients over a 5-year follow-up, (2)
whether LV global circumferential (GCS) and longitudinal
(GLS) strain with feature-tracking CMR show incremental
prognostic value over conventional CMR parameters in
STEMI patients and (3) whether the association between
global LV strain and prognosis is modulated by early intra-
venous metoprolol treatment.Methods
The METOCARD-CNIC trial was a multicenter, ran-
domized, parallel-group, single-blinded (to outcome eval-
uators) clinical trial (ClinicalTrials.gov identifier:
NCT01311700). The study design and protocol have been
previously described.15 Briefly, a total of 270 patients with
first anterior STEMI were randomized to receive up to
15 mg intravenous metoprolol before primary percutaneous
coronary intervention versus conventional therapy. Patients
presenting with Killip class III to IV acute heart failure, sys-
tolic blood pressure persistently <120 mm Hg, PR interval
>240 milliseconds (or type II to III atrioventricular block),
heart rate persistently <60 beats/min, or active treatment
with any b-blocker agent were excluded from the trial. All
patients, including those in control arm, received oral meto-
prolol (first dose 12 to 24 hours after reperfusion). CMR
was performed in 220 patients at 1 week (5 to 7 days) after
STEMI. There were no differences in demographic varia-
bles, cardiovascular risk profile and procedural characteris-
tics between patients receiving early intravenous
metoprolol and the controls.7 The study was approved by
the ethical committees and institutional review boards at
each participating center. All eligible patients gave written
informed consent.
The CMR data acquisition was performed with 1.5 and
3.0 T CMR scanners. The 2-, 3- and 4-chamber views and a
stack of contiguous short-axis slices to cover the whole LV
were acquired with steady-state free precession functional
cine imaging. Data acquisition parameters were: voxel size
1.6£ 2 mm, slice thickness 8 mm, gap 0 mm, cardiac
phases 25-30, TR 3.5, TE 1.7, flip angle 40, SENSE 1.5,averages 1, FOV 360£ 360 mm. Segmented inversion
recovery gradient echo sequence, acquired 10 to 15 minutes
after a cumulative dose of 0.2 mmol/kg intravenous gado-
linium contrast agent was employed for myocardial necro-
sis/fibrosis imaging. CMR data were analyzed with
dedicated software (QMass MR 7.5; Medis, Leiden, the
Netherlands) as described before.15 LVEF was determined
from the short-axis cine images with LV trabeculations
included within the blood pool. LGE was quantified accord-
ing to full-width-half-maximum method from short-axis
delayed enhancement images and expressed as the percent
of LV mass. The presence of microvascular obstruction
(MVO), defined as hypointense areas within the hyperen-
hanced zone on LGE images, was evaluated.
Feature-tracking CMR analysis was performed with ded-
icated software (cvi42 v5.3, Circle Cardiovascular Imaging,
Calgary, Canada). First, the LV endo- and epicardium were
manually delineated at end-diastole in short-axis and 2-, 3-
and 4-chamber long-axis views. In addition, the anterior
right ventricular insertion point, the mitral annulus and the
LV apex were defined. Short-axis slices covering the whole
LV were included in GCS analysis. Subsequently, the out-
lined myocardium borders were automatically tracked
throughout the cardiac cycle with fully automated feature-
tracking analysis. The quality of the myocardium tracking
was visually evaluated with manual adjustments of the con-
tours if necessary. Global time-strain curves were obtained
and peak GCS and GLS values were recorded.
The primary end point of the present analysis was the
occurrence of major adverse cardiac events (MACE) at 5-
year follow-up after STEMI. MACE was defined as the
composite of death, rehospitalization for heart failure, rein-
farction, and malignant ventricular arrhythmias (ventricular
fibrillation, sustained ventricular tachycardia), as in the pre-
specified METOCARD-CNIC trial end point.15 Readmis-
sions because of the heart failure were due to heart failure
decompensation or due to the indication for implantable
cardioverter defibrillator therapy. Clinical follow-up was
performed by telephone interview and access to hospital
reports. Clinical events for the 2-year follow-up8 were
blindly adjudicated by a committee but the extended fol-
low-up events were not adjudicated. Some events were
self-reported by the patient and in other cases a discharge
report was available. To evaluate the prognostic influence
of LV strain on outcomes, only the events occurring after
the first CMR scan, that is, 1 week after STEMI, were
included. In particular, all malignant ventricular arrhyth-
mias occurred earlier and were not included in the analysis.
Normally distributed continuous variables are presented
as mean and standard deviation and compared using inde-
pendent samples t tests. Non-normal data are reported as
medians, first and third quartiles and were compared with
Mann-Whitney U test. Categorical variables are presented
as counts and percentages and compared using the
Pearson’s Chi-square test. For the primary end point analy-
sis, patients were censored at the occurrence of the first
event. The impact of early intravenous metoprolol in the
overall METOCARD-CNIC trial population was evaluated
with Kaplan-Meier method and with Cox proportional haz-
ards regression model. Subsequently, Cox regression analy-
sis was performed in the cohort with available 1-week
Coronary Artery Disease/Prognostic Value of Feature-Tacking CMR in STEMI 41CMR scan to identify the conventional and feature-tracking
CMR variables associated with the primary end point. Haz-
ard ratios (HR) and 95% confidence intervals (CI) were cal-
culated and adjusted for demographic and clinical
variables. To evaluate the incremental prognostic value of
LV GCS and GLS over the conventional CMR parameters,
nested regression models were created and the global Chi-
square values were compared. To investigate if patient
prognosis was modulated by the interaction between global
LV strain and early intravenous metoprolol treatment,
patients were divided according to the median GCS and
GLS values and the randomization status (early intravenous
metoprolol vs. control group). The cumulative event rates
were estimated using Kaplan-Meier survival curves. In
addition, exploratory Cox regression analysis was per-
formed to compare the HR for the occurrence of primary
end point between individual groups. A 2-sided p-value of
<0.05 was statistically significant. All statistical analyses
were performed using IBM SPSS Statistics 23 (IBM,
Armonk, New York).Results
In the overall METOCARD-CNIC trial population of
270 patients (139 treated with early intravenous metoprolol
and 131 with conventional STEMI therapy) 214 patients
(79.3%) completed the 5-year follow-up and 48 patients
(17.8%) presented with MACE (Figure 1). Patients who
received early intravenous metoprolol had fewer cumula-
tive MACE (HR 0.500, 95% CI 0.277 to 0.903; p = 0.022)
and fewer heart failure admissions (HR 0.298, 95% CI
0.096 to 0.924; p = 0.036; Table 1). The Kaplan-Meier
curves for the occurrence of MACE in both treatment arms
are shown in Figure 2.
Among 220 patients who underwent 1-week CMR scan,
feature-tracking analysis was feasible in 215 patients (early
metoprolol group: N = 105 of 106; control group: N = 110
of 114) and they formed the population for the LV strain
analysis (Figure 1). A total of 185 patients (86.0%) com-
pleted the 5-year follow-up and 25 patients (11.6%) pre-
sented with MACE. Patients experiencing MACE had
higher body mass index, were more often diabetic and had
more pronounced LV systolic dysfunction (demonstrated
by impaired LVEF, GCS, and GLS) and greater infarct size
1 week after STEMI compared with patients without
MACE (Table 2). On univariable Cox regression analysis,
LV CMR imaging parameters (except for MVO) were sig-
nificantly associated with the occurrence of the primary
endpoint (Table 3). Each 1% increase in LV GCS was asso-
ciated with 21% increased risk of MACE whereas each 1%
increase in LV GLS was associated with 36% increased
risk of MACE. After adjusting for demographic and clinical
variables, the association between LV GCS and GLS with
the occurrence of MACE remained statistically significant
(Table 3). Moreover, after adjusting for demographic and
clinical variables also MVO was significantly associated
with the occurrence of the primary endpoint. To assess the
incremental prognostic value of GCS and GLS over con-
ventional CMR parameters, nested regression models were
created and global chi-square values were calculated
(Figure 3). Adding GLS to a model including LGE andLVEF significantly increased the chi-square value
(LGE + LVEF chi-square = 12.865, LGE + LVEF + GLS
chi-square = 18.459; p = 0.012). In contrast, the addition of
LV GCS or MVO to the model including LGE and LVEF
did not have statistically significant incremental prognostic
value.
To explore the interaction between LV GCS and GLS
and the effect of early intravenous metoprolol, 215 patients
with 1-week CMR feasible for feature-tracking analysis
(the LV strain population) were divided into 4 groups
according to the median LV GCS (13.1%; interquartile
range 10.0% to 16.5%) and GLS values (11.5%; inter-
quartile range 9.4% to 13.4%) and the randomization
status (early intravenous metoprolol vs. conventional ther-
apy). The crude event rates in each patient group are pre-
sented in Table 4. The Kaplan-Meier curves show
significant differences between groups for the cumulative
MACE (Figure 4). Patients with more impaired strain who
were treated with conventional STEMI therapy had the
highest event rates while the differences between other 3
groups were less pronounced. In the exploratory subgroup
analysis, patients with more impaired GLS (≥11.5%)
who received early intravenous metoprolol were 64% less
likely to experience MACE (HR 0.356, 95% CI 0.129 to
0.979; p = 0.045) than their counterparts with same degree
of GLS impairment but receiving conventional STEMI
therapy. A similar, but not statistically significant trend was
observed for patients with more impaired GCS (≥13.1%)
(HR for early metoprolol treatment 0.400, 95% CI 0.132 to
1.216; p = 0.106).Discussion
The present study demonstrated that (1) early intrave-
nous metoprolol has a long-term beneficial prognostic
value in STEMI patients, (2) LV GLS measured with fea-
ture-tracking CMR early after STEMI provides incremen-
tal prognostic value over LVEF and infarct size assessed
with LGE, and (3) the association between GCS, GLS,
and prognosis is modulated by early intravenous metopro-
lol treatment with the majority of MACE occurring in
patients with impaired LV strain treated with conventional
STEMI therapy.
The METOCARD-CNIC trial was the first randomized
control trial in the modern era of primary PCI in STEMI
that evaluated the cardioprotective effect of intravenous
b-blockers.7 Early intravenous administration of metoprolol
(before primary PCI) was associated with significant reduc-
tion of primary end point, the infarct size measured with
LGE CMR 1 week after STEMI.7 In addition, early intrave-
nous metoprolol administration was associated with a non-
significant trend toward reduced occurrence of prespecified
MACE (10.8% in the metoprolol group vs 18.3% in the
control group; p = 0.065) and a significant reduction in heart
failure readmissions (2.2% in the metoprolol group vs 6.9%
in the control group; p = 0.046) at a median follow-up of
2 years.8 In the present article, the impact of early intrave-
nous metoprolol treatment in the METOCARD-CNIC trial
population was reinvestigated with extended 5-year follow-
up data and significant reduction in both, MACE as well as
heart failure readmissions, was demonstrated. In addition,
Figure 1. Study flow diagram. CMR = cardiovascular magnetic resonance.
Table 1
The occurrence of MACE in patients according to the randomization status in the overall METOCARD-CNIC trial population
Metoprolol (N = 139) Control (N = 131) HR (95% CI) p Value
MACE* 17 (12.2%) 31 (23.7%) 0.500 (0.277-0.903) 0.022
Death 8 (5.8%) 8 (6.1%) 0.903 (0.339-2.405) 0.838
Cardiac death 3 (2.2%) 6 (4.6%)
Noncardiac deathy 5 (3.6%) 2 (1.5%)
HF admission 4 (2.9%) 12 (9.2%) 0.298 (0.096-0.924) 0.036
Reinfarction 1 (0.7%) 5 (3.8%) 0.179 (0.021-1.536) 0.117
Malignant ventricular arrhythmia 5 (3.6%) 10 (7.6%) 0.477 (0.163-1.397) 0.177
CI = confidence interval; HF = heart failure; HR = hazard ratio; MACE =major adverse cardiac events.
*A few patients experienced more than 1 event, however in MACE only the first event was included.
yAmong noncardiac deaths 6 were due to cancer and 1 due to hemoptysis (metoprolol group).
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intravenous metoprolol had more preserved global LV
strain and infarct zone circumferential strain after
STEMI.16,17 However, in the present analysis we have dem-
onstrated that patients with impaired LV strain, particularly
those with impaired GLS, who were treated with early
intravenous metoprolol had lower adverse event rates than
their counterparts with same degree of LV strain
impairment but receiving conventional STEMI therapy.
These results strengthen our current evidence of the benefi-
cial long-term prognostic effect of early intravenous meto-
prolol in STEMI patients with primary PCI and without
contraindications to b-blockers.
In recent years, several CMR techniques have emerged
to assess regional and global LV systolic function in
patients with acute myocardial infarction.18 Among these
techniques, feature-tracking CMR has gained prominenceas a fast and accurate modality for the assessment of LV
strain using standard cine images. Recently, the association
between multidirectional LV strain with feature-tracking
CMR after myocardial infarction and patients outcome has
been explored in 4 large patient cohorts.9−12 Eitel et al9
included 1,107 patients after myocardial infarction and
demonstrated an incremental prognostic value of LV GLS
for all-cause mortality but not for the occurrence of MACE,
over LVEF and infarct size. Gavara et al10 studied 323
patients after STEMI and showed that LV GLS rather than
GCS or global radial strain was an independent predictor of
MACE. However, in the multivariable models including
clinical and CMR variables GLS did not significantly
improve patients risk reclassification. Yoon et al11 and
Reindl et al12 demonstrated incremental prognostic value of
GLS with feature-tracking CMR over LVEF and CMR
markers of infarct severity for the occurrence of MACE in
Figure 2. Kaplan Meier estimates for cumulative major adverse cardiac event rates in the overall METOCARD-CNIC trial population.
Table 2
Clinical and CMR characteristics of patients with feature-tracking CMR analysis
Variable Overall (N = 215) MACE (N = 25) No MACE (N = 190) p Value
Age (years) 58.4 § 11.5 61.8 § 9.1 57.9 § 11.7 0.059
Men 187 (87%) 23 (92%) 164 (86%) 0.748
BMI (kg/m2) 27.3 (25.4-29.4) 28.1 (27.5-30.9) 26.7 (25.2-29.3) 0.006
Hypertension 84 (39%) 14 (56%) 70 (37%) 0.071
Diabetes mellitus 42 (20%) 9 (36%) 33 (17%) 0.029
Smoker* 136 (63%) 15 (60%) 121 (64%) 0.670
LGE (%) 22.0§13.3 28.4§14.1 21.1§13.0 0.009
Presence of MVO 126 (59%) 19 (76%) 107 (56%) 0.068
LVEF (%) 44.9§9.8 38.6§9.3 45.8§9.5 0.001
LV GCS (%) -13.5§4.0 -11.2§4.3 -13.8§3.9 0.002
LV GLS (%) -11.6§3.2 -9.1§3.0 -11.9§3.1 <0.001
Values are mean § SD, median (interquartile range) or n (%). BMI = body mass index; GCS = global circumferential strain; GLS = global longitudinal
strain; LGE = late gadolinium enhancement; LVEF = left ventricular ejection fraction; MACE =major adverse cardiac event; MVO =microvascular
obstruction.
* Smoker was defined as current or quitted <10 years ago.
Table 3
Clinical and CMR variables as predictors of the primary endpoint in patients with feature-tracking CMR analysis
Variable Univariable analysis Multivariable analysis*
HR 95% CI p Value HR 95% CI p Value
Age (years) 1.026 0.991-1.063 0.140
Men 1.696 0.400-7.195 0.473
BMI (kg/m2) 1.118 1.023-1.222 0.014
Hypertension 2.088 0.948-4.599 0.068
Diabetes mellitus 2.537 1.121-5.743 0.025
Smokery 0.831 0.373-1.850 0.650
LGE (%) 1.040 1.009-1.071 0.010 1.046 1.014-1.078 0.004
Presence of MVO 2.261 0.903-5.662 0.081 2.801 1.081-7.257 0.034
LVEF (%) 0.922 0.882-0.965 <0.001 0.908 0.868-0.951 <0.001
GCS (%) 1.208 1.076-1.356 0.001 1.228 1.094-1.378 <0.001
GLS (%) 1.362 1.180-1.573 <0.001 1.372 1.184-1.589 <0.001
BMI = body mass index; CI = confidence interval; GCS = global circumferential strain; GLS = global longitudinal strain; HR = hazard ratio; LGE = late
gadolinium enhancement; LVEF = left ventricular ejection fraction; MVO =microvascular obstruction.
* CMR variables were adjusted for demographic and clinical parameters (age, sex, BMI, hypertension, diabetes mellitus, smoking status).
y Smoker was defined as current or quitted <10 years ago.
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Figure 3. Incremental prognostic value of left ventricular strain with feature-tracking CMR. Bar graphs illustrate the prognostic value of cardiovascular
magnetic resonance (CMR) imaging parameters for the assessment of the occurrence of major adverse cardiac events, displayed by chi-square values on the
y-axis. GCS = global circumferential strain; GLS = left ventricular global longitudinal strain; LGE = late gadolinium enhancement; LVEF = left ventricular
ejection fraction; MVO =microvascular obstruction.
Table 4
The occurrence of MACE in patients according to the median GCS and GLS and the randomization status
GCS ≥13.1% GCS <13.1%
Control (N = 65) Metoprolol (N = 42) Control (N = 45) Metoprolol (N = 63)
MACE* 14 (21.5%) 4 (9.5%) 4 (8.9%) 3 (4.8%)
Death 3 (4.6%) 1 (2.4%) 1 (2.2%) 2 (3.2%)
Cardiac death 3 (4.6%) 0 0 0
Noncardiac deathy 0 1 (2.4%) 1 (2.2%) 2 (3.2%)
HF admission 9 (13.8%) 3 (7.1%) 1 (2.2%) 1 (1.6%)
Reinfarction 3 (4.6%) 0 2 (4.4%) 0
GLS ≥11.5% GLS <11.5%
Control (N = 58) Metoprolol (N = 49) Control (N = 52) Metoprolol (N = 56)
MACE* 15 (25.9%) 5 (10.2%) 3 (5.8%) 2 (3.6%)
Death 3 (5.2%) 1 (2.0%) 1 (1.9%) 2 (3.6%)
Cardiac death 3 (5.2%) 0 0 0
Non-cardiac deathy 0 1 (2.0%) 1 (1.9%) 2 (3.6%)
HF admission 10 (17.2%) 4 (8.2%) 0 0
Re-infarction 3 (5.2%) 0 2 (3.8%) 0
GCS = global circumferential strain; GLS = global longitudinal strain; HF = heart failure; MACE =major adverse cardiac event.
*One patient in the impaired GCS/GLS group treated with conventional therapy experienced 2 events, however in MACE only the first event was included.
yAll 4 noncardiac deaths were due to cancer.
44 The American Journal of Cardiology (www.ajconline.org)in 247 STEMI and 451 STEMI patients, respectively. Simi-
larly, our results show that both impaired LV GCS and
GLS were strong predictors of adverse cardiac events after
myocardial infarction and LV GLS analysis provided incre-
mental prognostic value over conventional CMR parame-
ters. Compared with the other studies, the patient
population in our study was homogenous, consisting of
anterior STEMI patients without signs of acute heart fail-
ure, prospectively included in the multicenter randomized
controlled clinical trial.7
The different prognostic value of LV GLS and GCS
might be the explained by the difference in LV mechanics
described by both indices. During acute myocardial infarc-
tion myocardial cell injury spreads from the endocardium
to the epicardium with increasing duration of coronaryocclusion and severity of ischemia; the so-called “wavefront
phenomenon of myocardial death.”19 Since the majority of
longitudinally oriented myocardial fibers are located in the
subendocardium20 the LV longitudinal systolic function
becomes impaired first. In contrast, the circumferential myo-
cardial fibers that are found in the LV midwall20 require a
greater degree of transmural myocardial injury to impact on
circumferential shortening. We may reasonably assume that
impaired LV GCS reflects more severe myocardial injury and
as such provides similar prognostic information to other
CMR parameters. In contrast, the ability of LV GLS to
account for the subendocardial infarct injury suggests that
this parameter is a more sensitive marker of LV systolic dys-
function that adds additional prognostic information above
other CMR parameters.
Figure 4. Kaplan Meier estimates for cumulative major adverse cardiac event rates according to the global left ventricular strain and the randomi-
zation status. (A) Patients were divided according to the global left ventricular circumferential strain (GCS) ≥13.1% (more impaired) vs <13.1% (more
preserved) and the treatment group (early intravenous metoprolol vs control group). (B) Patients were divided according to the global left ventricular longitu-
dinal strain (GLS) ≥11.5% (more impaired) vs <11.5% (more preserved) and the treatment group.
Coronary Artery Disease/Prognostic Value of Feature-Tacking CMR in STEMI 45Feature-tracking is a novel technique to assess LV strain
with CMR. Standardization of feature-tracking analysis as
well as the reference values for LV strain and the agreement
across various vendors of feature-tracking software are not
established.21 Furthermore, the evaluation of LV strain was
not a predefined study endpoint of the METOCARD-CNIC
trial. A limited number of events occurred during 5-year
follow-up of patients included in the METOCARD clinical
trial, which makes multivariable testing challenging, espe-
cially in the subgroup analysis. Of the initial 220 patients
who underwent 1-week CMR study in the METOCARD-
CNIC trial, 5 patients were excluded from the LV strain
analysis due to poor CMR cine image quality (arrhythmias,
metallic artifacts) which may have influenced our results.
However, 98% feasibility of strain assessment with feature-
tracking CMR is similar to what has been described
before.22,23 In addition, excellent intra- and interobserver
reproducibility of feature-tracking analysis in our institution
have been reported.16In conclusion, early intravenous metoprolol has a long-
term beneficial prognostic effect, particularly in patients
who were at a greater risk for the occurrence of MACE due
to severely impaired LV systolic function. Moreover, global
LV strain assessment with feature-tracking CMR early after
primary PCI provides important information in risk stratifi-
cation of STEMI patients. LV GLS offers incremental prog-
nostic value over traditional markers of LV injury, such as
LVEF and infarct size with LGE.Disclosures
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